2025-11-15 - Analysis Report
Okay, here's an analysis of Hims & Hers Health Inc. (HIMS) based on the provided data. The report is structured with numerical highlights followed by analysis for each section, and a comprehensive summary at the end.

## HIMS Stock Analysis - 2025-11-15

### 1. Performance vs. S&P 500 (VOO)

**Key Numbers:**

*   **HIMS Cumulative Return:** 140.63%
*   **VOO Cumulative Return:** 72.58%
*   **Absolute Divergence (HIMS - VOO):** 68.05%
*   **Relative Divergence:** 49.7 (Range: min -86.1 to max 321.5)

**Analysis:**

Hims & Hers Health Inc. (HIMS) is a telehealth company offering personalized health and wellness solutions. HIMS has significantly outperformed the S&P 500 (VOO) since the start of data. The relative divergence of 49.7 indicates that while HIMS has outperformed VOO, it's currently in the lower half of its historical outperformance range relative to VOO. This suggests that while still positive, its recent performance hasn't been as strong compared to its own history of divergence.

**Alpha, Beta Analysis:**

| Year       | CAGR    | MDD   | Alpha | Beta | Cap(B) |
|------------|---------|-------|-------|------|--------|
| 2019-2021  | -42.0%  | 74.4% | -81.0% | 0.0  | 1.5    |
| 2020-2022  | -19.0%  | 78.6% | -18.0% | -0.0 | 1.5    |
| 2021-2023  | -65.0%  | 78.6% | -67.0% | -0.1 | 2.0    |
| 2022-2024  | 119.0% | 79.4% | 98.0% | -0.0  | 5.5    |
| 2023-2025  | 145.0% | 80.8% | 82.0% | 0.1  | 8.4    |

**Analysis:**

*   **CAGR:** The Compound Annual Growth Rate shows highly variable performance. Recent years (2022-2025) demonstrate strong growth, while earlier periods show significant losses.
*   **MDD:** The Maximum Drawdown is consistently high, indicating significant risk and volatility.
*   **Alpha:** Alpha is generally negative in earlier periods, indicating underperformance relative to the market risk-free rate. Recent periods show very strong positive Alpha, which means HIMS has done much better than expected for the risk involved.
*   **Beta:** Beta values are around 0 to 0.1, suggesting HIMS's price is not as affected by broader market movements.
*   **Cap(B):** The market capitalization has grown significantly, particularly in recent years.

### 2. Recent Stock Price Movement

**Key Numbers:**

*   **Current Price:** $36.98
*   **Previous Close:** $36.05
*   **Change:** 2.58%
*   **5-day Moving Average:** $38.57
*   **20-day Moving Average:** $44.30
*   **60-day Moving Average:** $49.60

**Analysis:**

The current price shows a 2.58% increase from the previous close, indicating a recent positive price movement. However, the price is below all the moving averages (5, 20, and 60 days), which suggests a short-term downtrend. The price increase relative to the previous close may indicate a potential rebound after the downtrend.

### 3. Technical Indicators and Market Risk

**Key Numbers:**

*   **Market Risk Indicator (MRI):** 0.8 (Medium Investment)
*   **RSI:** 15.55 (Oversold)
*   **PPO:** -1.89
*   **Delta_Previous_Relative_Divergence (20-day):** -5.2 (Decreasing)
*   **Expected Return:** 8.9% (vs S&P 500, long-term)
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (17 shares - Very Safe - MRI:0.90) Monthly invest 1.3% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-10-01)

**Analysis:**

*   **MRI:** A MRI of 0.8 suggests a medium investment recommendation based on the risk profile.
*   **RSI:** An RSI of 15.55 indicates an oversold condition, which *could* signal a potential buying opportunity. However, oversold conditions can persist, so it shouldn't be the sole basis for a decision.
*   **PPO:** A negative PPO suggests that price momentum is trending downward.
*   **Delta_Previous_Relative_Divergence:** The negative change in relative divergence over the past 20 days indicates a recent period of underperformance compared to its historical divergence from the S&P 500.
*   **Expected Return:** An expected return of 8.9% above the S&P 500 (over a 2+ year investment horizon) is attractive and suggests potential long-term value.
*   **Market React:** The reported price change {'price': 36.98, 'previousClose': 36.05, 'change': 2.58} reflects a modest bounce, suggesting the market is reacting to news or technical levels after a potential decline.
*   **Hybrid Signal:** The "Hybrid Signal" recommendation (Buy 100% of cash) is based on the MRI of 0.9, suggesting a very safe investment.

### 4. Recent News & Significant Events

**Key Headlines:**

*   **Family Alleges Hims & Hers Health, Inc.’s Rush Into Mental Healthcare Violated Washington Law and Resulted in Son’s Death:** This is a serious negative event that could impact the company's reputation and potentially lead to legal liabilities.
*   **Hims & Hers Bets on Lab Testing to Boost Growth:** This suggests a strategic move to expand their services and drive revenue growth.
*   **Hims & Hers Introduces Labs, a Holistic, In-Depth Testing Experience:**  This reinforces the previous headline and highlights the company's expansion into lab testing.
*   **Healthcare Stock to Consider / Quality Healthcare Stocks:**  Some analysts view HIMS favorably, which can provide investor confidence.

**Analysis:**

The news is mixed. The lawsuit allegation is a significant concern. However, the expansion into lab testing is a positive development that could drive future growth. The analyst opinions provide a more balanced view.

### 4-2. Analyst Opinions

**Key Numbers:**

*   **Consensus:** Hold
*   **Mean Rating:** 2.86 (~Hold)
*   **Opinions:** 12
*   **Target Price (Avg/High/Low):** $46.67 / $85.00 / $25.00

**Analysis:**

The analyst consensus is "Hold," suggesting a neutral outlook on the stock. The average target price of $46.67 indicates a potential upside from the current price. However, the wide range between the high and low target prices ($85.00 vs. $25.00) reflects significant uncertainty among analysts.

### 5. Recent Earnings Analysis

| Date       | EPS  | Revenue    |
|------------|------|------------|
| 2025-11-03 | 0.07 | 0.60 B$    |
| 2025-08-04 | 0.19 | 0.54 B$    |
| 2025-05-05 | 0.22 | 0.59 B$    |
| 2024-11-04 | 0.35 | 0.40 B$    |
| 2025-11-03 | 0.35 | 0.40 B$    |

**Analysis:**

* **EPS (Earnings Per Share):** EPS has shown variability over the recent quarters. Recent EPS figures indicate fluctuations, with the latest data showing a decrease.
* **Revenue:** Revenue has generally increased over the period, indicating growth in the company's sales.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter      | Revenue   | Profit Margin |
|--------------|-----------|---------------|
| 2025-09-30   | $0.60B    | 73.80%       |
| 2025-06-30   | $0.54B    | 76.39%       |
| 2025-03-31   | $0.59B    | 73.50%       |
| 2024-12-31   | $0.48B    | 76.81%       |
| 2024-09-30   | $0.40B    | 79.16%       |

**Capital and Profitability:**

| Quarter      | Equity    | ROE      |
|--------------|-----------|----------|
| 2025-09-30   | $0.58B    | 2.72%    |
| 2025-06-30   | $0.56B    | 7.55%    |
| 2025-03-31   | $0.55B    | 9.01%    |
| 2024-12-31   | $0.48B    | 5.46%    |
| 2024-09-30   | $0.44B    | 17.18%   |

**Analysis:**

*   **Revenue:** Revenue is consistently increasing, showing strong top-line growth.
*   **Profit Margin:** Profit margins are high and relatively stable, indicating efficient operations.
*   **Equity:** Equity is increasing, suggesting financial stability and growth.
*   **ROE:** ROE has fluctuated but generally remains positive, indicating profitability and efficient use of shareholder equity.

### 7. Comprehensive Summary

Hims & Hers Health Inc. (HIMS) presents a mixed picture.

**Positives:**

*   **Strong Historical Outperformance:** HIMS has significantly outperformed the S&P 500, demonstrating strong growth potential.
*   **Positive Expected Return:** The expected long-term return is attractive.
*   **Revenue Growth:** Consistent revenue increases and healthy profit margins indicate strong business performance.
*   **Strategic Initiatives:** The company is actively expanding its services (e.g., lab testing) to drive growth.

**Negatives:**

*   **High Volatility:** The high Maximum Drawdown and variable CAGR demonstrate significant risk.
*   **Analyst Uncertainty:** The wide range in analyst target prices reflects uncertainty about the company's future.
*   **Negative News:** The lawsuit allegation is a major concern that could impact the company's reputation and financials.
*   **Short-Term Downtrend:** The stock price is below key moving averages, indicating a potential short-term downtrend.
*    **Decrease EPS:** Decrease EPS in the recent quarter

**Overall:**

HIMS is a high-growth, high-risk stock. The potential for significant returns is present, but investors should be aware of the potential downsides, particularly the negative news surrounding the lawsuit. The "Hold" consensus from analysts suggests a cautious approach. The recent drop below moving averages combined with oversold RSI suggests a possible short-term buying opportunity for those with a high-risk tolerance and long-term investment horizon, but this should be approached with caution considering the lawsuit and analyst uncertainty.
